Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients aged ≥18 years old at the initiation of InO treatment
* Patients with relapsed/refractory B-cell ALL
* Patients who initiated InO monotherapy between Feb'2017 and Feb'2022 and are CD22 positive
* Ph+ patients who have failed treatment with at least 1 TKI
You may not be if
Patient not completing at least 1 cycle of InO therapy • Patient on InO in combination with chemotherapy
Clareo Health | A Study of Patients Who Received Inotuzumab Ozogamicin for B-cell ALL (Acute Lymphoblastic Leukemia) That Occurred Again After the Last Treatment
